Sign up to access all valuation multiples
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
2020
220
LTM Revenue $23.0M
Last FY EBITDA -$567M
$388M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nuvation Bio has a last 12-month revenue (LTM) of $23.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Nuvation Bio achieved revenue of $7.9M and an EBITDA of -$567M.
Nuvation Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nuvation Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.0M | XXX | $7.9M | XXX | XXX | XXX |
| Gross Profit | $15.3M | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 10% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$567M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7201% | XXX | XXX | XXX |
| EBIT | -$369M | XXX | -$593M | XXX | XXX | XXX |
| EBIT Margin | -1604% | XXX | -7527% | XXX | XXX | XXX |
| Net Profit | -$347M | XXX | -$568M | XXX | XXX | XXX |
| Net Margin | -1508% | XXX | -7214% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 22, 2025, Nuvation Bio's stock price is $3.
Nuvation Bio has current market cap of $938M, and EV of $388M.
See Nuvation Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $388M | $938M | XXX | XXX | XXX | XXX | $-1.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 22, 2025, Nuvation Bio has market cap of $938M and EV of $388M.
Nuvation Bio's trades at 49.3x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Nuvation Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nuvation Bio has a P/E ratio of -2.7x.
See valuation multiples for Nuvation Bio and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $938M | XXX | $938M | XXX | XXX | XXX |
| EV (current) | $388M | XXX | $388M | XXX | XXX | XXX |
| EV/Revenue | 16.8x | XXX | 49.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 25.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | -3.0x | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNuvation Bio's last 12 month revenue growth is 288%
Nuvation Bio's revenue per employee in the last FY averaged $36K, while opex per employee averaged $2.7M for the same period.
Nuvation Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nuvation Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nuvation Bio and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 288% | XXX | 293% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7201% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -6913% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6658% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 7537% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nuvation Bio acquired XXX companies to date.
Last acquisition by Nuvation Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Nuvation Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Nuvation Bio founded? | Nuvation Bio was founded in 2020. |
| Where is Nuvation Bio headquartered? | Nuvation Bio is headquartered in United States of America. |
| How many employees does Nuvation Bio have? | As of today, Nuvation Bio has 220 employees. |
| Who is the CEO of Nuvation Bio? | Nuvation Bio's CEO is Dr. David T. Hung,M.D.. |
| Is Nuvation Bio publicy listed? | Yes, Nuvation Bio is a public company listed on NYS. |
| What is the stock symbol of Nuvation Bio? | Nuvation Bio trades under NUVB ticker. |
| When did Nuvation Bio go public? | Nuvation Bio went public in 2021. |
| Who are competitors of Nuvation Bio? | Similar companies to Nuvation Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Nuvation Bio? | Nuvation Bio's current market cap is $938M |
| What is the current revenue of Nuvation Bio? | Nuvation Bio's last 12 months revenue is $23.0M. |
| What is the current revenue growth of Nuvation Bio? | Nuvation Bio revenue growth (NTM/LTM) is 288%. |
| What is the current EV/Revenue multiple of Nuvation Bio? | Current revenue multiple of Nuvation Bio is 16.8x. |
| Is Nuvation Bio profitable? | Yes, Nuvation Bio is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Nuvation Bio? | Nuvation Bio's last 12 months FCF is -$131M. |
| What is Nuvation Bio's FCF margin? | Nuvation Bio's last 12 months FCF margin is -567%. |
| What is the current EV/FCF multiple of Nuvation Bio? | Current FCF multiple of Nuvation Bio is -3.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
